Resistance of Pseudomonas Aeruginosa to Antibiotics in the Constanta Infectious Diseases Hospital During the SARS-COV2 Pandemic

Pseudomonas aeruginosa is a gram-negative, rod-shaped bacterium (bacillus), which can cause diseases in plants, animals, and humans.

A species of considerable medical importance, Pseudomonas aeruginosa is a multi-antibiotic-resistant pathogen recognized for its ubiquity, its intrinsically advanced antibiotic resistance mechanisms, and its association with serious diseases: nosocomial infections (e.g.: ventilator-associated pneumonia) ⁠ or sepsis.

Analysis of the resistance of the Pseudomonas bacillus to antibiotics during April 2020-September 2021 at the Constanta Clinical Hospital for Infectious Diseases.

A retrospective study on a group of 36 patients infected with Pseudomonas aeruginosa aged between 6-70 years who were hospitalized between April 2020 and September 2021 in the Constanta Clinical Hospital for Infectious Diseases.

We found that of the total number of patients infected with the Pioceanic bacillus, the majority were male (25-69.4%), and the rest were female (11-31.6%). Of the total number of patients, 2 were children aged 6 and 10, respectively. The main methods of germ isolation were: sputum-20 isolates, blood-1 isolates, auricular-2, throat-1, purulent secretion-2, secretion-3, tracheal aspirate-2, urine culture-5 isolates. Some 8 (22.2%) were from the ATI ward, from the adult ward some 19 (52.7%), and from the external HIV ward, some 6 (16.6%) and some 2 (5.5%) in the Pediatric ward.

Regarding antibiotic resistance, we had resistance to the following antibiotics: Amikacin 9 (25%), Ciprofloxacin 9 (25%), Piperacillin-Tazobactam 16 (44.4%), Imipenem 13 (36%), Meropenem 12 (30.3%), Ceftriaxone 1 (2.7%), and sensitivity we found: Amikacin 14 (38.8%), Ciprofloxacin 23 (63.8%), Pipercilintazobactam 23 (63.8%), Meropenem 12 (30.3%), Imipenem 23 (63.8%), Ceftriaxone.